Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Variants of SOS2 are a rare cause of Noonan syndrome with particular predisposition for lymphatic complications

This article has been updated

Abstract

RASopathies are caused by variants in genes encoding components or modulators of the RAS/MAPK signaling pathway. Noonan syndrome is the most common entity among this group of disorders and is characterized by heart defects, short stature, variable developmental delay, and typical facial features. Heterozygous variants in SOS2, encoding a guanine nucleotide exchange factor for RAS, have recently been identified in patients with Noonan syndrome. The number of published cases with SOS2-related Noonan syndrome is still limited and little is known about genotype–phenotype correlations. We collected previously unpublished clinical and genotype data from 17 individuals carrying a disease-causing SOS2 variant. Most individuals had one of the previously reported dominant pathogenic variants; only four had novel changes at the established hotspots for variants that affect protein function. The overall phenotype of the 17 patients fits well into the spectrum of Noonan syndrome and is most similar to the phenotype observed in patients with SOS1-related Noonan syndrome, with ectodermal anomalies as common features and short stature and learning disabilities as relatively infrequent findings compared to the average Noonan syndrome phenotype. The spectrum of heart defects in SOS2-related Noonan syndrome was consistent with the known spectrum of cardiac anomalies in RASopathies, but no specific heart defect was particularly predominating. Notably, lymphatic anomalies were extraordinarily frequent, affecting more than half of the patients. We therefore conclude that SOS2-related Noonan syndrome is associated with a particularly high risk of lymphatic complications that may have a significant impact on morbidity and quality of life.

This is a preview of subscription content, access via your institution

Access options

Buy this article

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Clinical photographs documenting the craniofacial and clinical phenotype of patients with SOS2-related NS.

Similar content being viewed by others

Change history

  • 05 March 2021

    After publication of this article, one family withdrew their permission to use photos from an affected mother and her son in Figure 1. The respective facial photographs have been deleted from Figure 1.

References

  1. Grant AR, Cushman BJ, Cave H, Dillon MW, Gelb BD, Gripp KW, et al. Assessing the gene-disease association of 19 genes with the RASopathies using the ClinGen gene curation framework. Hum Mutat. 2018;39:1485–93.

    Article  Google Scholar 

  2. Bhoj EJ, Yu Z, Guan Q, Ahrens-Nicklas R, Cao K, Luo M, et al. Phenotypic predictors and final diagnoses in patients referred for RASopathy testing by targeted next-generation sequencing. Genet Med. 2017;19:715–8.

    Article  Google Scholar 

  3. Cizmarova M, Hlinkova K, Bertok S, Kotnik P, Duba HC, Bertalan R, et al. New mutations associated with rasopathies in a Central European population and genotype-phenotype correlations. Ann Hum Genet. 2016;80:50–62.

    Article  CAS  Google Scholar 

  4. Cordeddu V, Yin JC, Gunnarsson C, Virtanen C, Drunat S, Lepri F, et al., Activating mutations affecting the Dbl homology domain of SOS2 cause Noonan syndrome. Hum Mutat. 2015;36:1080–7.

    Article  CAS  Google Scholar 

  5. Yamamoto GL, Aguena M, Gos M, Hung C, Pilch J, Fahiminiya S, et al. Rare variants in SOS2 and LZTR1 are associated with Noonan syndrome. J Med Genet. 2015;52:413–21.

    Article  CAS  Google Scholar 

  6. Pierre S, Bats AS, Coumoul X. Understanding SOS (son of sevenless). Biochem Pharmacol. 2011;82:1049–56.

    Article  CAS  Google Scholar 

  7. Simanshu DK, Nissley DV, McCormick F. RAS proteins and their regulators in human disease. Cell. 2017;170:17–33.

    Article  CAS  Google Scholar 

  8. Ding Y, Hu XY, Song YN, Cao BY, Liang XJ, Li HD, et al. A report on a girl of Noonan syndrome 9 presenting with bilateral lower limbs lymphedema. Chin Med J. 2019;132:480–2.

    Article  Google Scholar 

  9. Lepri F, De Luca A, Stella L, Rossi C, Baldassarre G, Pantaleoni F, et al. SOS1 mutations in Noonan syndrome: molecular spectrum, structural insights on pathogenic effects, and genotype-phenotype correlations. Hum Mutat. 2011;32:760–72.

    Article  CAS  Google Scholar 

  10. Bessis D, Miquel J, Bourrat E, Chiaverini C, Morice-Picard F, Abadie C, et al. Dermatological manifestations in Noonan syndrome: a prospective multicentric study of 129 patients positive for mutation. Br J Dermatol. 2019;180:1438–48.

    Article  CAS  Google Scholar 

  11. Altmuller F, Lissewski C, Bertola D, Flex E, Stark Z, Spranger S, et al., Genotype and phenotype spectrum of NRAS germline variants. Eur J Hum Genet. 2017;25:823–31.

    Article  Google Scholar 

  12. Kouz K, Lissewski C, Spranger S, Mitter D, Riess A, Lopez-Gonzalez V, et al. Genotype and phenotype in patients with Noonan syndrome and a RIT1 mutation. Genet Med. 2016;18:1226–34.

    Article  CAS  Google Scholar 

  13. Gelb BD, Cave H, Dillon MW, Gripp KW, Lee JA, Mason-Suares H, et al. ClinGen’s RASopathy Expert Panel consensus methods for variant interpretation. Genet Med. 2018;20:1334–45.

    Article  Google Scholar 

  14. Bobot M, Coen M, Simon C, Daniel L, Habib G, Serratrice J. DRESS syndrome with thrombotic microangiopathy revealing a Noonan syndrome: Case report. Medicine. 2018;97:e0297.

    Article  Google Scholar 

  15. Maridet C, Sole G, Morice-Picard F, Taieb A. Hypertrophic neuropathy in Noonan syndrome with multiple lentigines. Am J Med Genet A. 2016;170:1570–2.

    Article  Google Scholar 

  16. Zenker M, Horn D, Wieczorek D, Allanson J, Pauli S, van der Burgt I, et al. SOS1 is the second most common Noonan gene but plays no major role in cardio-facio-cutaneous syndrome. J Med Genet. 2007;44:651–6.

    Article  CAS  Google Scholar 

  17. Joyce S, Gordon K, Brice G, Ostergaard P, Nagaraja R, Short J, et al. The lymphatic phenotype in Noonan and cardiofaciocutaneous syndrome. Eur J Hum Genet. 2016;24:690–6.

    Article  CAS  Google Scholar 

  18. Jones GE, Mansour S. An approach to familial lymphoedema. Clin Med. 2017;17:552–7.

    Article  Google Scholar 

  19. Li D, March ME, Gutierrez-Uzquiza A, Kao C, Seiler C, Pinto E, et al. ARAF recurrent mutation causes central conducting lymphatic anomaly treatable with a MEK inhibitor. Nat Med. 2019;25:1116–22.

    Article  CAS  Google Scholar 

  20. Biko DM, Reisen B, Otero HJ, Ravishankar C, Victoria T, Glatz AC, et al. Imaging of central lymphatic abnormalities in Noonan syndrome. Pediatr Radiol. 2019;49:586–92.

    Article  Google Scholar 

  21. Kratz CP, Franke L, Peters H, Kohlschmidt N, Kazmierczak B, Finckh U, et al. Cancer spectrum and frequency among children with Noonan, Costello, and cardio-facio-cutaneous syndromes. Br J Cancer. 2015;112:1392–7.

    Article  CAS  Google Scholar 

  22. Ly KI, Blakeley JO. The diagnosis and management of neurofibromatosis type 1. Med Clin North Am. 2019;103:1035–54.

    Article  Google Scholar 

  23. Denayer E, Devriendt K, de Ravel T, Van Buggenhout G, Smeets E, Francois I, et al. Tumor spectrum in children with Noonan syndrome and SOS1 or RAF1 mutations. Genes Chromosomes Cancer. 2010;49:242–52.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors thank the subjects and their families for participating in this study. We thank Natacha Fillot for invaluable technical assistance and Nathalie Pouvreau for help in data management of the French patients.

Funding

This work was supported by the ERN-ITHACA networking (LM and MT) and grants from European Joint Programme on Rare Diseases (NSEuroNet to HC, MT, and MZ [01GM1602A]), German Federal Ministry of Education and Research—BMBF (German Network for RASopathy Research “GeNeRARe” to MZ [01GM1519A]), German Research Foundation (ZE 524/10-2 to MZ, KU 1240/9-2 to KK), Associazione Italiana per la Ricerca sul Cancro (IG21614 to MT), and Italian Ministry of Health (Ricerca Corrente 2019 and 2020 to MT and 2019 to ADL). LM is the coordinator of HCP AUO S.Orsola ERN-ITHACA, Bologna, Italy.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Martin Zenker.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lissewski, C., Chune, V., Pantaleoni, F. et al. Variants of SOS2 are a rare cause of Noonan syndrome with particular predisposition for lymphatic complications. Eur J Hum Genet 29, 51–60 (2021). https://doi.org/10.1038/s41431-020-00708-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41431-020-00708-6

This article is cited by

Search

Quick links